Certain HPV16 antibodies may predict oropharyngeal cancer survival
the ONA take:
Certain human papillomavirus (HPV)-16 antibodies in the blood was associated with improved survival rates among patients with HPV-related oropharyngeal carcinoma, according to a new study.
For the study, researchers analyzed blood samples from 209 patients with previously untreated oropharyngeal carcinoma. Of those, 96 had confirmed HPV-positive disease. Samples were screened for HPV16 antibodies E1, E4-7, L1, L2, and the N-terminal and C-terminal fragments of E2.
Results showed that patients with any of the E antibodies had improved overall and progression-free survival versus those who tested negative for the antibodies. HPV-positive patients who tested positive for NE2, E1, or E6 antibodies also had a reduced mortality and disease progression risk.
Researchers found no survival advantage for people who tested positive for L antibodies.
Clinical trials are currently ongoing to evaluate whether vaccines can stimulate these antibodies to improve outcomes in patients with HPV-related cancers.
Certain HPV-16 antibodies in the blood associated with improved survival in HPV-related oropharyngeal carcinoma.
- Acupuncture an Effective Alternative Treatment for Cancer-Related Fatigue
- Response to Anemia Treatment Differs in Lymphoma, Multiple Myeloma
- Compound in Teas, Peas, Soybeans May Increases Prostate Cancer Risk
- Fertility Preservation in Male Adolescents and Young Adults With Cancer
- Social, Psychiatric Variables Reduce Cognitive Functioning, QoL in HNC
- HPV and Cancer (Fact Sheet)
- Pain Control More Easily Achieved With Nurse-Led Education in Bone Metastases
- Using Nutrition-Based Strategies to Manage Adverse Effects of Cancer
- Palliative Care Associated With Decreased Costs For Patients With Advanced Cancer
- A Case of Immunotherapy-Induced Myocarditis Concomitant to MG in Lung Cancer
- Online Learning Modules Improve Exercise Counseling, But Not Participation
- ASCO Issues Statement Addressing Alcohol and Cancer
- Duloxetine May Improve AI-Associated Joint Pain in Early Stage Breast Cancer
- Axillary Lymph Node Dissection Predictive for Lymphedema in Breast Cancer
- Drug Combination Does Not Extend Glioblastoma Survival
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|